Details

Autor(en) / Beteiligte

• Oluniyi, Paul E
• Ajogbasile, Fehintola V
• Zhou, Shuntai
• Fred-Akintunwa, Iyanuoluwa
• Polyak, Christina S
• Ake, Julie A
• Tovanabutra, Sodsai
• Iroezindu, Michael
• Rolland, Morgane
• Happi, Christian T

Titel

HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria

Ist Teil von

• AIDS (London), 2022-01, Vol.36 (1), p.137-146

Ort / Verlag

England: Lippincott Williams & Wilkins

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• This study was designed to provide information on the genetic diversity of HIV-1 and drug resistance mutations in Nigeria, as there is limited understanding of variants circulating in the country. We used an advanced next-generation sequencing platform, Primer ID, to: investigate the presence of high and low abundance drug resistance mutations; characterize preexisting Integrase Strand Transfer Inhibitor (INSTI) mutations in antiretroviral therapy (ART)-experienced but dolutegravir-naive individuals; detect recent HIV-1 infections and characterize subtype diversity from a cohort of people with HIV-1 (PWH). HIV-1 subtype analysis revealed the predominance of CRF02_AG and subtype G in our study population. At detection sensitivity of 30% abundance, drug resistance mutations (DRMs) were identified in 3% of samples. At a sensitivity level of 10%, DRMs were identified in 27.3% of samples. We did not detect any major INSTI mutation associated with dolutegravir-resistance. Only one recent infection was detected in our study population. Our study suggests that dolutegravir-containing antiretroviral regimens will be effective in Nigeria. Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country.